查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2012510

男性健康体检市场：按产品类型、应用和最终用户划分 - 2026-2032年全球市场预测

Mens Health Diagnostics Market by Product Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年男性健康检查市场价值 162.7 亿美元，预计到 2026 年将成长至 181.5 亿美元，复合年增长率为 11.69%，到 2032 年将达到 352.9 亿美元。

主要市场统计数据
基准年 2025 162.7亿美元
预计年份：2026年 181.5亿美元
预测年份 2032 352.9亿美元
复合年增长率 (%) 11.69%

最新男性健康筛检概览，阐述了临床需求、更严格的法规和技术融合如何改变男性健康筛检的开发和实施。

现代男性健康筛检趋势的特征是临床需求、技术创新和不断发展的诊疗路径的融合。消费者和临床医生越来越需要侵入性更小、特异性更高、且与慢性病管理更紧密结合的诊断方法。同时，随着监管力度加大和保险公司期望的提高，临床有效性、真实临床实践中的疗效证据以及成本效益的标准也日益严格。这些趋势迫使製造商、侦测网路和医疗保健系统重新思考其产品开发时间表和商业化策略。

技术、临床效用期望和医疗保健服务模式的重大系统性变革，从根本上改变了诊断技术的创新和传播。

多项变革正在重塑男性健康检查的设计、检验和实施方式，并影响医疗机构的运作模式。精准医疗技术正从概念验证迈向常规临床应用，从而能够针对前列腺疾病和心血管风险等疾病提供更有针对性的筛检和监测方法。同时，影像技术也在不断发展，透过先进的软体、人工智慧驱动的影像解读以及跨模态整合，在提高诊断准确性的同时，也简化了工作流程。

关税政策和贸易措施的变化如何使诊断的整个价值链中的采购、定价策略和供应商选址决策变得复杂。

新关税措施及相关贸易政策的出台，进一步加剧了诊断供应链中供应商、製造商和服务供应商的营运复杂性。资本密集成像系统和专用诊断试剂进口成本的增加，可能会改变医院和诊断中心的采购决策，进而影响设备更新週期和资金配置。面对不断上涨的跨国成本，供应商可能需要重新评估区域製造地，协商新的供应商合约条款，或在地采购，以缓解利润率下降的局面。

将产品模式、医疗保健环境和临床应用与策略发展和商业化重点连结起来的可操作细分洞察。

精细化的细分观点能够清楚地识别出创新和应用压力最大的领域。在评估产品类型时，影像系统对于结构和功能评估仍然至关重要，每种影像方式——电脑断层扫描 (CT)、磁振造影(MRI)、核子医学影像、超音波和 X 光——都发挥独特的诊断作用。除了成像之外，临床实验室检测透过生物标记检测和基因检测，从分子层面提供了更深入的诊断讯息，从而实现更早期的疾病检测和更个性化的疾病表征。当这些产品类别在医疗团队中有效整合时，便可形成互补的诊断路径，进而增强临床决策能力。

决定美洲、欧洲、中东、非洲和亚太地区诊断策略应如何调整的区域趋势和市场状况。

区域趋势既影响需求模式，也影响临床应用路径。在美洲，整合的医疗保健系统和整合的检测网络在临床流程方面展现出显着的改进，为满足支付方期望的解决方案创造了有利环境。相较之下，欧洲、中东和非洲（EMEA）的市场环境复杂多样，法规结构和报销机制各不相同，因此需要灵活的市场进入策略和针对特定区域的证据策略。同时，亚太地区的特点是基础设施快速扩张，并高度重视国内製造和区域分销网络，这影响采购政策和伙伴关係模式。

透过技术整合、证据产生和附加价值服务，在诊断领域确立领导地位的策略竞争行动和能力。

在男性健康筛检领域，竞争优势越来越取决于企业能否将技术优势与可靠的临床证据和可扩展的服务模式结合。主要企业正着力提升硬体和软体的协同效应，开发可与分析和决策支援工具互通的影像诊断平台，以减少诊断差异并增强临床医师的信心。同时，投资于高特异性生物标记检测和基因平台的企业则透过宣传其在早期检测和预后预测方面更高的准确性来脱颖而出。

在政策变化的背景下，製造商和供应商需要采取切实可行的策略措施来加速产品采用，证明其临床效用，并确保其商业性韧性。

产业领导企业应优先采取三项策略措施，将新兴趋势转化为可持续的竞争优势。首先，投资于严谨的临床检验项目，将诊断结果与治疗决策和患者预后明确关联起来，从而消除支付方的顾虑，并促进在整个医疗服务路径中的应用。其次，重组经营模式，透过灵活的资金筹措、捆绑式服务或基于结果的合约来降低应用门槛，从而共用应用风险，并在医疗服务路径层面展现价值。这些措施将为医疗系统的购买者和支付方提供更清晰的决策指南。

采用稳健的混合方法研究途径，结合相关人员访谈、临床文献综述、政策分析和情境测试来检验见解。

本研究整合了对关键相关人员的访谈、对同行评审临床文献的系统性回顾以及对监管和支付方政策趋势的分析，以确保获得平衡且基于证据的观点。主要访谈对象包括临床医生、实验室管理人员、技术负责人和采购专家，旨在了解实际情况和推广应用的障碍。次要分析则着重于近期发表的临床试验、指引更新和调查方法论文，以全面检验各项技术在诊疗路径中的临床效度和潜在效用。

对诊断趋势进行明确整合，强调模式整合、复杂的证据要求和具有持久影响的稳健商业化途径。

总体而言，男性健康筛检领域正处于一个关键的转折点，技术成熟、支付方审查以及不断演变的医疗服务模式相互交织，重塑着创新者和医疗服务提供者的优先事项。影像学和临床检测的互补性日益增强，为早期发现和更个人化的疾病管理铺平了道路。同时，对临床效用和治疗过程层面证据的需求不断增长，促使人们重新评估商业化策略和伙伴关係模式，以确保临床医生的认可和支付方的覆盖范围。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：男性健康体检市场：依产品类型划分

  • 医学影像系统
    • 电脑断层扫描
    • 磁振造影
    • 核子医学扫描术诊断
    • 超音波
    • X射线
  • 临床试验
    • 生物标记检测
    • 基因检测

第九章：男性健康体检市场：依应用领域划分

  • 心血管诊断
  • 糖尿病监测
  • 前列腺癌诊断
  • 泌尿系统疾病的诊断

第十章：男性健康体检市场：依最终用户划分

  • 门诊手术中心
  • 诊所
  • 诊断中心
  • 医院

第十一章：男性健康体检市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十二章：男性健康体检市场：依群体划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十三章：男性健康体检市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十四章：美国男性健康体检市场

第十五章：中国男性健康体检市场

第十六章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Becton Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Danaher Corporation
  • DiaSorin SpA
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd
  • Hologic, Inc.
  • Johnson & Johnson
  • Koninklijke Philips NV
  • Myriad Genetics, Inc.
  • QIAGEN NV
  • Quest Diagnostics Incorporated
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
Product Code: MRR-431388EE3BC2

The Mens Health Diagnostics Market was valued at USD 16.27 billion in 2025 and is projected to grow to USD 18.15 billion in 2026, with a CAGR of 11.69%, reaching USD 35.29 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 16.27 billion
Estimated Year [2026] USD 18.15 billion
Forecast Year [2032] USD 35.29 billion
CAGR (%) 11.69%

A contemporary overview of mens health diagnostics showing how clinical demand, regulatory rigor, and technology convergence are reshaping development and delivery

The modern mens health diagnostics landscape is defined by the convergence of clinical need, technological innovation, and evolving care pathways. Consumers and clinicians increasingly demand diagnostic approaches that are less invasive, more specific, and better integrated with chronic disease management. At the same time, regulatory scrutiny and payer expectations are raising the bar for clinical validation, real-world performance evidence, and cost-effectiveness. These dynamics are prompting manufacturers, laboratory networks, and health systems to rethink product development timelines and commercialization strategies.

Transitioning from legacy diagnostic paradigms, stakeholders are investing in hybrid models that combine imaging modalities with molecular and genetic assays to produce richer diagnostic signals. Integration across care settings is accelerating, with a focus on connecting ambulatory and hospital workflows to deliver timely diagnostic data into treatment decisions. Consequently, strategic planners must balance near-term operational pressures with longer-term investments in interoperability, data analytics, and evidence generation to sustain competitive differentiation and support reimbursement pathways.

Key systemic shifts in technology, clinical utility expectations, and care delivery models that are fundamentally altering diagnostics innovation and adoption

Several transformative shifts are reshaping how mens health diagnostics are designed, validated, and deployed across care settings. Precision technologies have moved beyond proof of concept to routine clinical application, enabling more targeted screening and monitoring approaches for conditions such as prostate disease and cardiovascular risk. Concurrently, imaging has evolved through enhanced software, AI-assisted interpretation, and cross-modality integration that boosts diagnostic accuracy while supporting workflow efficiency.

Another major inflection point is the elevation of value-based care principles, which prioritizes outcomes and long-term cost avoidance. This forces diagnostic developers to demonstrate not just analytic validity, but clinical utility and pathway-level impact. Moreover, the commercialization environment is changing; strategic partnerships between manufacturers, labs, and health systems are becoming essential to scale adoption and secure favorable reimbursement. Taken together, these forces create both opportunities and obligations for innovators to produce robust clinical evidence, drive clinician acceptance, and align diagnostics with evolving care incentives.

How evolving tariff policies and trade measures are complicating procurement, pricing strategies, and supplier footprint decisions across the diagnostics value chain

The introduction of new tariff measures and related trade policies creates an added layer of operational complexity for suppliers, manufacturers, and service providers in the diagnostics supply chain. Increased import costs for capital-intensive imaging systems and specialized assay reagents can alter procurement decisions at hospitals and diagnostic centers, influencing upgrade cycles and capital allocation. Suppliers facing higher cross-border costs may need to reassess regional manufacturing footprints, negotiate new supplier terms, or localize components to mitigate margin erosion.

These policy changes also affect pricing strategies and contract negotiations, because end users operate under constrained budgets and are sensitive to total cost of ownership. As a result, organizations that proactively model tariff impacts and engage stakeholders across procurement, clinical operations, and finance can better preserve access to advanced diagnostics. Furthermore, the need for transparency around cost drivers will intensify, prompting some vendors to offer alternative commercial structures such as managed services, reagent rental, or outcome-based contracting to ease budgetary pressures and maintain adoption momentum.

Actionable segmentation insights linking product modalities, care settings, and clinical applications to strategic development and commercialization priorities

A granular segmentation lens clarifies where innovation and adoption pressures are most acute. When evaluating product types, imaging systems remain critical for structural and functional assessment, with modalities including computed tomography, magnetic resonance imaging, nuclear imaging, ultrasound, and X-ray each serving distinct diagnostic roles. Parallel to imaging, laboratory tests add molecular depth through biomarker assays and genetic testing, enabling earlier detection and more personalized disease characterization. Together, these product classes form complementary diagnostic pathways that bolster clinical decision-making when integrated effectively across care teams.

From an end-user perspective, care settings differ substantially in workflow requirements and capital intensity. Ambulatory surgical centers, clinics, diagnostic centers, and hospitals each demand tailored solutions that address throughput, staffing models, and reimbursement layouts. Applications likewise concentrate clinical and commercial focus on cardiovascular diagnostics, diabetes monitoring, prostate cancer diagnostics, and urological disorder diagnostics, where unmet needs and established care protocols create varied opportunities for tools that deliver actionable insights. Understanding these segment-specific drivers supports targeted development, evidence generation, and commercialization plans that align product capabilities to the realities of each setting and use case.

Regional dynamics and differentiated market realities that determine how diagnostics strategies must adapt across the Americas, Europe/Middle East/Africa, and Asia-Pacific

Regional dynamics shape both demand patterns and the pathway to clinical adoption. In the Americas, integrated health systems and consolidated laboratory networks create fertile ground for solutions that demonstrate measurable pathway improvements and align with payer expectations. In contrast, Europe, the Middle East & Africa presents a heterogeneous landscape where diverse regulatory frameworks and reimbursement mechanisms require adaptable go-to-market approaches and localized evidence strategies. Meanwhile, Asia-Pacific is characterized by rapid infrastructure expansion and a strong emphasis on domestic manufacturing and regional distribution networks, which influences procurement preferences and partnership models.

These geographic distinctions also influence clinical practice norms, investment in imaging capabilities, and the scale-up speed for novel assays. Therefore, companies should tailor regulatory planning, evidence generation, and commercial partnerships to regional realities. Leveraging local clinical champions, investing in region-specific health economics evidence, and adapting service delivery models can accelerate adoption and ensure that innovations translate into sustainable clinical and financial value across markets.

Strategic competitive behaviors and capabilities that define leadership in diagnostics through technology integration, evidence generation, and value-added services

Competitive positioning in mens health diagnostics increasingly depends on the ability to integrate technological strengths with robust clinical evidence and scalable service models. Leading organizations emphasize hardware-software synergy, developing imaging platforms that interoperate with analytics and decision-support tools to reduce interpretation variability and enhance clinician confidence. At the same time, companies investing in high-specificity biomarker assays and genetic platforms are differentiating through claims of earlier detection and greater prognostic precision.

Moreover, successful players are extending their value propositions beyond product delivery to include implementation support, training, and outcomes measurement. This shift reflects the recognition that selling a diagnostic without the associated change management is unlikely to drive widespread clinical uptake. Strategic alliances with laboratory service providers and health systems can amplify reach while easing the burden of evidence generation. Consequently, firms that combine technological excellence with pragmatic commercialization tactics and real-world performance data position themselves favorably in a competitive and evidence-driven marketplace.

Practical strategic initiatives for manufacturers and providers to accelerate adoption, prove clinical utility, and safeguard commercial resilience amid policy shifts

Industry leaders should prioritize a trio of strategic moves to translate emerging trends into durable advantage. First, invest in rigorous clinical validation programs that explicitly tie diagnostic outputs to treatment decisions and patient outcomes, thereby addressing payer concerns and facilitating adoption across care pathways. Second, restructure commercial models to lower adoption barriers through flexible financing, bundled service offerings, or outcome-aligned contracts that share implementation risk and demonstrate pathway-level value. These initiatives will create clearer decision points for health system purchasers and payers.

Third, deepen partnerships across the ecosystem, engaging academic centers, community hospitals, and diagnostic laboratories to accelerate real-world evidence collection and to create reproducible workflows. By coordinating these elements, organizations can shorten time-to-value and foster clinician champions. Finally, maintain an agile supply chain and regulatory strategy to respond quickly to policy shifts and tariff-related disruptions, safeguarding continuity of supply and preserving competitive pricing. Together, these measures will strengthen market resilience and enhance the probability of long-term adoption.

Robust mixed-methods research approach combining stakeholder interviews, clinical literature review, policy analysis, and scenario testing to validate insights

This research synthesizes primary stakeholder interviews, systematic review of peer-reviewed clinical literature, and an analysis of regulatory and payer policy developments to ensure a balanced and evidence-driven perspective. Primary interviews included clinicians, laboratory directors, technology leaders, and procurement specialists to capture operational realities and adoption barriers. Secondary analysis focused on recently published clinical trials, guideline updates, and methodology papers to triangulate the technologies' clinical validity and potential utility within care pathways.

In addition, the methodology incorporated a review of public policy changes and procurement frameworks to assess their implications for capital equipment and consumables. Data synthesis emphasized cross-validation across sources to mitigate single-source bias and to surface consistent themes. Finally, findings were stress-tested through scenario planning to examine how shifts in trade policies, reimbursement environments, and clinical practice might influence strategic priorities and operational decisions for developers and providers.

Conclusive synthesis of diagnostics trends highlighting integration of modalities, elevated evidence requirements, and resilient commercialization pathways for sustained impact

In sum, the mens health diagnostics arena is at a pivotal juncture where technological maturation, payer scrutiny, and shifting care delivery models converge to reshape priorities for innovators and providers. Imaging modalities and laboratory assays are increasingly complementary, creating pathways for earlier detection and more personalized disease management. At the same time, heightened requirements for clinical utility and pathway-level evidence are prompting a reassessment of commercialization strategies and partnership models to secure clinician acceptance and payer coverage.

Looking forward, organizations that proactively build integrated solutions, prioritize transparent evidence development, and adapt commercial structures to meet budgetary realities will be best positioned to capture clinical and economic value. Navigating tariff and policy headwinds requires deliberate supply chain planning and flexible contracting approaches. By aligning technological capabilities with pragmatic evidence and commercialization tactics, stakeholders can accelerate meaningful improvements in diagnostic care while building resilient business models.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Mens Health Diagnostics Market, by Product Type

  • 8.1. Imaging Systems
    • 8.1.1. Computed Tomography
    • 8.1.2. Magnetic Resonance Imaging
    • 8.1.3. Nuclear Imaging
    • 8.1.4. Ultrasound
    • 8.1.5. X Ray
  • 8.2. Laboratory Tests
    • 8.2.1. Biomarker Assays
    • 8.2.2. Genetic Testing

9. Mens Health Diagnostics Market, by Application

  • 9.1. Cardiovascular Diagnostics
  • 9.2. Diabetes Monitoring
  • 9.3. Prostate Cancer Diagnostics
  • 9.4. Urological Disorder Diagnostics

10. Mens Health Diagnostics Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Clinics
  • 10.3. Diagnostic Centers
  • 10.4. Hospitals

11. Mens Health Diagnostics Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Mens Health Diagnostics Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Mens Health Diagnostics Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Mens Health Diagnostics Market

15. China Mens Health Diagnostics Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. Abbott Laboratories
  • 16.6. Becton Dickinson and Company
  • 16.7. Bio-Rad Laboratories, Inc.
  • 16.8. bioMerieux SA
  • 16.9. Danaher Corporation
  • 16.10. DiaSorin S.p.A.
  • 16.11. Exact Sciences Corporation
  • 16.12. F. Hoffmann-La Roche Ltd
  • 16.13. Hologic, Inc.
  • 16.14. Johnson & Johnson
  • 16.15. Koninklijke Philips N.V.
  • 16.16. Myriad Genetics, Inc.
  • 16.17. QIAGEN N.V.
  • 16.18. Quest Diagnostics Incorporated
  • 16.19. Siemens Healthineers AG
  • 16.20. Sysmex Corporation
  • 16.21. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MENS HEALTH DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES MENS HEALTH DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA MENS HEALTH DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY NUCLEAR IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY NUCLEAR IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY NUCLEAR IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY X RAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY X RAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY X RAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY BIOMARKER ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY BIOMARKER ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY BIOMARKER ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY CARDIOVASCULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY CARDIOVASCULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY CARDIOVASCULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY DIABETES MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY DIABETES MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY DIABETES MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY UROLOGICAL DISORDER DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY UROLOGICAL DISORDER DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY UROLOGICAL DISORDER DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS MENS HEALTH DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS MENS HEALTH DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS MENS HEALTH DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS MENS HEALTH DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS MENS HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS MENS HEALTH DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE MENS HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE MENS HEALTH DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE MENS HEALTH DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE MENS HEALTH DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE MENS HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE MENS HEALTH DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST MENS HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST MENS HEALTH DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST MENS HEALTH DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST MENS HEALTH DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST MENS HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST MENS HEALTH DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC MENS HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC MENS HEALTH DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC MENS HEALTH DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC MENS HEALTH DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC MENS HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC MENS HEALTH DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN MENS HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN MENS HEALTH DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN MENS HEALTH DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN MENS HEALTH DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN MENS HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN MENS HEALTH DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. GCC MENS HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GCC MENS HEALTH DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. GCC MENS HEALTH DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 117. GCC MENS HEALTH DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2032 (USD MILLION)
  • TABLE 118. GCC MENS HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. GCC MENS HEALTH DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION MENS HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION MENS HEALTH DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION MENS HEALTH DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION MENS HEALTH DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION MENS HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION MENS HEALTH DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS MENS HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS MENS HEALTH DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS MENS HEALTH DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS MENS HEALTH DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS MENS HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS MENS HEALTH DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. G7 MENS HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. G7 MENS HEALTH DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. G7 MENS HEALTH DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 135. G7 MENS HEALTH DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2032 (USD MILLION)
  • TABLE 136. G7 MENS HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. G7 MENS HEALTH DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. NATO MENS HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. NATO MENS HEALTH DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. NATO MENS HEALTH DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 141. NATO MENS HEALTH DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2032 (USD MILLION)
  • TABLE 142. NATO MENS HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. NATO MENS HEALTH DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. UNITED STATES MENS HEALTH DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. UNITED STATES MENS HEALTH DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. UNITED STATES MENS HEALTH DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 148. UNITED STATES MENS HEALTH DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2032 (USD MILLION)
  • TABLE 149. UNITED STATES MENS HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. UNITED STATES MENS HEALTH DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. CHINA MENS HEALTH DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. CHINA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. CHINA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 154. CHINA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2032 (USD MILLION)
  • TABLE 155. CHINA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. CHINA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)